Bristol-Myers Squibb (BMY) said Monday that its drug Breyanzi achieved "high, lasting response rates" among patients with relapsed or refractory marginal zone lymphoma in a phase 2 study.
The company said 95.5% of 66 evaluable patients showed an overall response, while 62.1% showed a complete response.
At 24 months, 88.6% sustained a response, 85.7% achieved progression-free survival, and 90.4% showed overall survival, the company said.
Median survival for patients with marginal zone lymphoma with multiple relapses is 3 to 5 years, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.